RecruitingPhase 2NCT06174220
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
Studying Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hamilton Health Sciences Corporation
- Principal Investigator
- Jason D Roberts, MD MASMcMaster University and Population Health Research Institute
- Intervention
- Tideglusib(drug)
- Enrollment
- 120 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (17)
- University of Calgary, Calgary, Alberta, Canada
- University of British Columbia, Vancouver, British Columbia, Canada
- Victoria Cardiac Arrhythmia Trials Inc., Victoria, British Columbia, Canada
- NL Health Services, St. John's, Newfoundland and Labrador, Canada
- Nova Scotia Health, Halifax, Nova Scotia, Canada
- Hamilton General Hospital, Hamilton, Ontario, Canada
- Kingston General Hospital, Kingston, Ontario, Canada
- London Health Sciences Centre, London, Ontario, Canada
- Newmarket Electrophysiologist Research Group 'NERG', Newmarket, Ontario, Canada
- University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Heart Health Institute Research Inc, Scarborough Village, Ontario, Canada
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- St. Michael's Hospital, Toronto, Ontario, Canada
- Montreal Heart Institute, Montreal, Quebec, Canada
- McGill University Health Centre, Montreal, Quebec, Canada
- +2 more locations on ClinicalTrials.gov
Collaborators
Canadian Institutes of Health Research (CIHR) · Canadian SADS · AMO Pharma Limited · Hearts in Rhythm Organization (HiRO) · Population Health Research Institute
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06174220 on ClinicalTrials.govOther trials for Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07050160Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic VariantLexeo Therapeutics
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06109181Gene Therapy for ACM Due to a PKP2 Pathogenic VariantLexeo Therapeutics
See all trials for Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant →